Genmab A/S (GMAB)
NASDAQ: GMAB · IEX Real-Time Price · USD
28.75
+1.06 (3.83%)
May 1, 2024, 4:00 PM EDT - Market closed
Genmab Employees
Genmab had 2,204 employees on December 31, 2023. The number of employees increased by 544 or 32.77% compared to the previous year.
Employees
2,204
Change (1Y)
544
Growth (1Y)
32.77%
Revenue / Employee
$1,107,347
Profits / Employee
$292,532
Market Cap
18.80B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 2,204 | 544 | 32.77% |
Dec 31, 2022 | 1,660 | 448 | 36.96% |
Dec 31, 2021 | 1,212 | 431 | 55.19% |
Dec 31, 2020 | 781 | 233 | 42.52% |
Dec 31, 2019 | 548 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Koninklijke Philips | 69,656 |
Laboratory Corporation of America Holdings | 67,000 |
Molina Healthcare | 18,000 |
STERIS | 17,100 |
The Cooper Companies | 15,000 |
Illumina | 13,360 |
BeiGene | 10,600 |
Waters | 7,900 |
GMAB News
- 1 day ago - Pfizer, Genmab get full FDA approval for cervical-cancer drug - Market Watch
- 1 day ago - TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical Cancer - Business Wire
- 1 day ago - FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical Cancer - Business Wire
- 2 days ago - Transactions in Connection with Share Buy-back Program Genmab - GlobeNewsWire
- 15 days ago - Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024 - GlobeNewsWire
- 23 days ago - Transactions in Connection with Share Buy-back Program - GlobeNewsWire
- 4 weeks ago - Biotech giant Genmab to acquire Seattle company ProfoundBio in $1.8B deal - GeekWire
- 4 weeks ago - Genmab Buys ProfoundBio for $1.8B to Boost Oncology Portfolio - Investopedia